Cargando…

Management of diabetes mellitus in patients with chronic kidney disease

Glycemic control is essential to delay or prevent the onset of diabetic kidney disease. There are a number of glucose-lowering medications available but only a fraction of them can be used safely in chronic kidney disease and many of them need an adjustment in dosing. The ideal target hemoglobin A1c...

Descripción completa

Detalles Bibliográficos
Autores principales: Hahr, Allison J., Molitch, Mark E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5469199/
https://www.ncbi.nlm.nih.gov/pubmed/28702221
http://dx.doi.org/10.1186/s40842-015-0001-9
_version_ 1783243545877938176
author Hahr, Allison J.
Molitch, Mark E.
author_facet Hahr, Allison J.
Molitch, Mark E.
author_sort Hahr, Allison J.
collection PubMed
description Glycemic control is essential to delay or prevent the onset of diabetic kidney disease. There are a number of glucose-lowering medications available but only a fraction of them can be used safely in chronic kidney disease and many of them need an adjustment in dosing. The ideal target hemoglobin A1c is approximately 7 % but this target is adjusted based on the needs of the patient. Diabetes control should be optimized for each individual patient, with measures to reduce diabetes-related complications and minimize adverse events. Overall care of diabetes necessitates attention to multiple aspects, including reducing the risk of cardiovascular disease, and often, multidisciplinary care is needed.
format Online
Article
Text
id pubmed-5469199
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-54691992017-07-12 Management of diabetes mellitus in patients with chronic kidney disease Hahr, Allison J. Molitch, Mark E. Clin Diabetes Endocrinol Review Article Glycemic control is essential to delay or prevent the onset of diabetic kidney disease. There are a number of glucose-lowering medications available but only a fraction of them can be used safely in chronic kidney disease and many of them need an adjustment in dosing. The ideal target hemoglobin A1c is approximately 7 % but this target is adjusted based on the needs of the patient. Diabetes control should be optimized for each individual patient, with measures to reduce diabetes-related complications and minimize adverse events. Overall care of diabetes necessitates attention to multiple aspects, including reducing the risk of cardiovascular disease, and often, multidisciplinary care is needed. BioMed Central 2015-06-04 /pmc/articles/PMC5469199/ /pubmed/28702221 http://dx.doi.org/10.1186/s40842-015-0001-9 Text en © Hahr and Molitch; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review Article
Hahr, Allison J.
Molitch, Mark E.
Management of diabetes mellitus in patients with chronic kidney disease
title Management of diabetes mellitus in patients with chronic kidney disease
title_full Management of diabetes mellitus in patients with chronic kidney disease
title_fullStr Management of diabetes mellitus in patients with chronic kidney disease
title_full_unstemmed Management of diabetes mellitus in patients with chronic kidney disease
title_short Management of diabetes mellitus in patients with chronic kidney disease
title_sort management of diabetes mellitus in patients with chronic kidney disease
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5469199/
https://www.ncbi.nlm.nih.gov/pubmed/28702221
http://dx.doi.org/10.1186/s40842-015-0001-9
work_keys_str_mv AT hahrallisonj managementofdiabetesmellitusinpatientswithchronickidneydisease
AT molitchmarke managementofdiabetesmellitusinpatientswithchronickidneydisease